tetano
Editor, Senior Moderator
Front Immunol. 2020 Mar 25;11:431. doi: 10.3389/fimmu.2020.00431. eCollection 2020.
Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin.
Gr?deland G[SUP]1[/SUP], Baranowska-Hustad M[SUP]1[/SUP], Abadejos J[SUP]2[/SUP], Blane TR[SUP]2[/SUP], Teijaro J[SUP]2[/SUP], Nemazee D[SUP]2[/SUP], Bogen B[SUP]1[/SUP].
Author information
Abstract
Novel and more broadly protective vaccines against influenza are needed to efficiently meet antigenic drift and shift. Relevant to this end, the stem domain of hemagglutinin (HA) is highly conserved, and antibodies specific for epitopes located to the stem have been demonstrated to be able to confer broad protection against various influenza subtypes. However, a remaining challenge is to induce antibodies against the poorly immunogenic stem by vaccination strategies that can be scaled up for prophylactic vaccination of the general population. Here, we have developed DNA vaccines where the conserved stem domain of HA from influenza A/PR/8/34 (H1N1) and A/Shanghai/2/2013 (H7N9) was targeted toward MHC class II molecules on antigen-presenting cells (APC) for increased immunogenicity. Each of these vaccines induced antibodies that cross-reacted with other subtypes in the corresponding phylogenetic influenza groups. Importantly, when mixing the MHCII-targeted stem domains from H1N1 and H7N9 influenza viruses into one vaccine bolus, we observed broad protection against candidate stains from both phylogenetic groups 1 and 2.
Copyright ? 2020 Gr?deland, Baranowska-Hustad, Abadejos, Blane, Teijaro, Nemazee and Bogen.
KEYWORDS:
APC-targeted antigen; DNA vaccine; MHCII; VH1-69; hemagglutinin (HA); stem domain
PMID:32269566PMCID:PMC7112135DOI:10.3389/fimmu.2020.00431
Free full text
Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin.
Gr?deland G[SUP]1[/SUP], Baranowska-Hustad M[SUP]1[/SUP], Abadejos J[SUP]2[/SUP], Blane TR[SUP]2[/SUP], Teijaro J[SUP]2[/SUP], Nemazee D[SUP]2[/SUP], Bogen B[SUP]1[/SUP].
Author information
Abstract
Novel and more broadly protective vaccines against influenza are needed to efficiently meet antigenic drift and shift. Relevant to this end, the stem domain of hemagglutinin (HA) is highly conserved, and antibodies specific for epitopes located to the stem have been demonstrated to be able to confer broad protection against various influenza subtypes. However, a remaining challenge is to induce antibodies against the poorly immunogenic stem by vaccination strategies that can be scaled up for prophylactic vaccination of the general population. Here, we have developed DNA vaccines where the conserved stem domain of HA from influenza A/PR/8/34 (H1N1) and A/Shanghai/2/2013 (H7N9) was targeted toward MHC class II molecules on antigen-presenting cells (APC) for increased immunogenicity. Each of these vaccines induced antibodies that cross-reacted with other subtypes in the corresponding phylogenetic influenza groups. Importantly, when mixing the MHCII-targeted stem domains from H1N1 and H7N9 influenza viruses into one vaccine bolus, we observed broad protection against candidate stains from both phylogenetic groups 1 and 2.
Copyright ? 2020 Gr?deland, Baranowska-Hustad, Abadejos, Blane, Teijaro, Nemazee and Bogen.
KEYWORDS:
APC-targeted antigen; DNA vaccine; MHCII; VH1-69; hemagglutinin (HA); stem domain
PMID:32269566PMCID:PMC7112135DOI:10.3389/fimmu.2020.00431
Free full text